Karolinska Development elects Rosenlew to board
This article was originally published in Scrip
Karolinska Development, the early stage biotech investment company linked to the Karolinska Institute, has elected Michael Rosenlew to its board. Mr Rosenlew was previously a managing partner and member of the executive committee of IK Investment Partners. Prior to that he held both financial and managerial positions in a number of Finnish companies, including the Amer Group.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.